Groundbreaking research presented at the AIDS 2026 conference suggests that a monthly oral PrEP pill could be manufactured for as little as US$3 per year. However, a new report from aidsmap highlights a troubling gap: Latin American countries are currently excluded from generic licensing agreements, leaving millions without access to this affordable prevention tool.

Why the $3 Price Tag Matters

The estimated cost of US$3 per year for a monthly PrEP pill represents a dramatic reduction from current market prices. This price point would make HIV prevention financially feasible for low- and middle-income countries, where the burden of new infections remains highest. The low cost is attributed to advances in manufacturing and the potential for generic production once patents expire or are voluntarily licensed.

Currently, oral PrEP is available as a daily pill, which costs significantly more and requires consistent adherence. A monthly formulation could improve adherence and reduce healthcare system burdens, making it a game-changer in the global fight against HIV.

The Licensing Divide: Latin America Left Behind

Despite the promise of affordable generic PrEP, the report reveals that Latin America is not included in current voluntary licensing agreements between pharmaceutical companies and generic manufacturers. These agreements typically cover countries in Africa and Asia, where HIV prevalence is high, but exclude middle-income regions like Latin America.

This exclusion means that public health systems in Latin American countries will continue to pay high prices for branded PrEP, limiting its availability. Activists argue that this is a missed opportunity to curb HIV incidence in the region, where key populations such as men who have sex with men and transgender women are disproportionately affected.

What Could Change?

  • Expanded licensing: Advocacy groups are urging companies to include Latin American countries in future licensing deals.
  • Patent challenges: Some countries may pursue compulsory licenses or patent oppositions to enable local generic production.
  • Regional cooperation: Joint procurement mechanisms could negotiate better prices with manufacturers.

Global Impact and Next Steps

The affordability of PrEP is critical to achieving the UNAIDS goal of ending AIDS as a public health threat by 2030. If generic versions are not available in Latin America, the region risks falling behind in prevention efforts.

The report calls on governments, pharmaceutical companies, and global health agencies to address this inequity. Public health experts emphasize that the cost of inaction will be measured in new HIV infections and preventable deaths.

“We have the tools to prevent HIV, but they are only useful if they reach those who need them,” said a spokesperson for the European AIDS Treatment Group.

Key Takeaways

  • A monthly PrEP pill could cost as little as US$3 per year to manufacture.
  • Generic licensing agreements currently exclude Latin America, keeping prices high there.
  • Expanding licensing and regional cooperation are essential to ensure equitable access.
  • Affordable PrEP is vital to ending the HIV epidemic by 2030.